Lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder who report clinically significant impairment in executive function: Results from a randomized, double-blind, placebo-controlled study

Journal of Clinical Psychiatry

Volumn 74, Issue 7, 2013, Pages 694-702

  Adler, Lenard A ^a   Dirks, Bryan ^b   Deas, Patrick F ^b   Raychaudhuri, Aparna ^b   Dauphin, Matthew R ^b   Lasser, Robert A ^b,e   Weisler, Richard H ^c,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHIRE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e SYNEOS HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISDEXAMFETAMINE; PLACEBO; PSYCHOSTIMULANT AGENT;

ADULT; AGITATION; ANOREXIA; ARM FRACTURE; ARTICLE; ATTENTION DEFICIT DISORDER; BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION ADULT; BEHAVIORAL REGULATION INDEX; BODY WEIGHT; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; CONTROLLED STUDY; DECREASED APPETITE; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; EARLY TERMINATION OF CLINICAL TRIAL; EFFECT SIZE; ERECTILE DYSFUNCTION; EXECUTIVE FUNCTION; FALLING; FATIGUE; FEMALE; FOOD POISONING; HEART RATE; HUMAN; HYPERHIDROSIS; INFLUENZA; INSOMNIA; IRRITABILITY; LIBIDO; MAJOR CLINICAL STUDY; MALE; METACOGNITION INDEX; MIGRAINE; MOOD DISORDER; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIUS FRACTURE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RECTUM DISEASE; RHINOPHARYNGITIS; SCORING SYSTEM; SELF REPORT; SIDE EFFECT; SKIN INJURY; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 84880979565     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.12m08144     Document Type: Article

References (53)

1. Faraone SV, Biederman J, Mick E. The age dependent decline of attention deficit hyperactivity disorder: a meta analysis of follow up studies. Psychol Med. 2006;36(2):159-165.
2. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006;163(4):716-723.
3. Biederman J, Faraone SV, Spencer TJ, et al. Functional impairments in adults with self reports of diagnosed ADHD: a controlled study of 1001-adults in the community. J Clin Psychiatry. 2006;67(4):524-540.
4. Weiss MD, Weiss Jr. A guide to the treatment of adults with ADHD. J Clin Psychiatry. 2004;65(suppl 3):27-37.
5. Rosler M, Casas M, Konofal E, et al. Attention deficit hyperactivity disorder in adults. World J Biol Psychiatry. 2010;11(5):684-698.
6. Gibbins C, Weiss M. Clinical recommendations in current practice guidelines for diagnosis and treatment of ADHD in adults. Curr Psychiatry Rep. 2007;9(5):420-426.
7. Gioia GA, Isquith PK, Retzlaff PD, et al. Confirmatory factor analysis of the Behavior Rating Inventory of Executive Function (BRIEF) in a clinical sample. Child Neuropsychol. 2002;8(4):249-257.
8. Gioia GA, Isquith PK, Guy SC, et al. BRIEF: Behavior Ratinginventory of Executive Function: Professional Manual. Lutz, FL: Psychological Assessment Resources; 2000.
9. Brown TE. Executive functions and attention deficit hyperactivity disorder: implications of two conflicting views. Int J Disabil Dcv Educ. 2006;53(1):35-46.
10. Castellanos FX, Sonuga Barke EJ, Milham MP, et al. Characterizing cognition in ADHD: beyond executive dysfunction. Trends Cogn Sci. 2006;10(3):117-123.
11. Barkley RA. Behavioral inhibition, sustained attention, and executive functions: constructing a unifying theory of ADHD. Psychol Bull. 1997;121(1):65-94.
12. Willcutt EG, Doyle AE, Nigg JT, et al. Validity of the executive function theory of attention deficit/hyperactivity disorder: a meta analytic review. Biol Psychiatry. 2005;57(11):1336-1346.
13. Kessler RC, Green JG, Adler LA, et al. Structure and diagnosis of adult attention deficit/hyperactivity disorder: analysis of expanded symptom criteria from the Adult ADHD Clinical Diagnostic Scale. Arch Gen Psychiatry. 2010;67(11):1168-1178.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.
15. Bell AS. A critical review of ADHD diagnostic criteria: what to address in the DSM 5.JAttenDisord. 2011;15(1):3-10.
16. Biederman J, Petty CR, Fried R, et al. Stability of executive function deficits into young adult years: a prospective longitudinal follow up study of grown up males with ADHD. Acta Psychiatr Scand. 2007;116(2):129-136.
17. Biederman J, Petty CR, Doyle AE, et al. Stability of executive function deficits in girls with ADHD: a prospective longitudinal follow up study into adolescence. Dcv Neuropsychol. 2008;33(1):44-61.
18. Biederman J, Petty C, Fried R, et al. Impact of psychometrically defined deficits of executive functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 2006;163(10): 1730-1738.
19. Biederman J, Monuteaux MC, Doyle AE, et al. Impact of executive function deficits and attention deficit/hyperactivity disorder (ADHD) on academic outcomes in children. J Consult Clin Psychol. 2004;72(5):757-766.
20. Brown TE, LandgrafJM. Improvements in executive function correlate with enhanced performance and functioning and health related quality of life: evidence from 2-large, double blind, randomized, placebo controlled trials in ADHD. Postgrad Med. 2010;122(5):42-51.
21. Swanson J, Baler lID, Volkow ND. Understanding the effects of stimulant medications on cognition in individuals with attention deficit hyperactivity disorder: a decade of progress. Neuropsychopharmacology. 2011;36(1):207-226.
22. Biederman J, Petty CR, Fried R, et al. Discordance between psychometric testing and questionnaire based definitions of executive function deficits in individuals with ADHD. J Atten Disord. 2008;12(1):92-102.
23. Barkley RA, Fischer M. Predicting impairment in major life activities and occupational functioning in hyperactive children as adults: self reported executive function (EF) deficits versus EF tests. Dcv Neuropsychol. 2011;36(2):137-161.
24. Nigg JT, Willcutt EG, Doyle AE, et al. Causal heterogeneity in attention deficit/hyperactivity disorder: do we need neuropsychologically impaired subtypes? Biol Psychiatry. 2005;57(11):1224-1230.
25. Brown TE, Reichel PC, Quinlan DM. Executive function impairments in high IQ adults with ADHD. J Atten Disord. 2009;13(2):161-167.
26. Shallice T, Burgess PW Deficits in strategy application following frontal lobe damage in man. Brain. 1991;114(pt 2):727-741.
27. Biederman J, Petty CR, Fried R, et al. Can self reported behavioral scales assess executive function deficits? a controlled study of adults with ADHD. J Nerv Ment Dis. 2007;195(3):240-246.
28. Roth RM, Isquith PK, Gioia GA. Behavior Rating Inventory of Executive Function Adult Version (BRIEF A). Lutz, FL: Psychological Assessment Resources; 1999.
29. Biederman J, Mick E, Fried R, et al. Are stimulants effective in the treatment of executive function deficits? results from a randomized double blind study of OROS methylphenidate in adults with ADHD. EurNeuropsychopharmacol. 2011;21(7):508-515.
30. Brown TE, Brams M, Gao J, et al. Open label administration of lisdexamfetamine dimesylate improves executive function impairments and symptoms of attention deficit/hyperactivity disorder in adults. Postgrad Med. 2010;122(5):7-17.
31. Adler L, Kulaga A, Shaw D, et al. Pilot study of relationship of neuropsychological and symptom assessment measures of attention and executive. Presented at the 2011-Annual Meeting of the American Academy of Child and Adolescent Psychiatry; October18-23,2011; Toronto, Ontario, Canada.
32. Vyvanse [package insert]. Wayne, PA: Shire US; 2012.
33. Adler LA, Goodman DW, Kollins SH, et al; 303-Study Group. Double blind, placebo controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373.
34. DuPaul GJ, Power TJ, Anastopoulos AD, et al. ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretation. New York, NY: Guilford Press; 1998.
35. Adler L, Cohen J. Diagnosis and evaluation of adults with attention deficit/hyperactivity disorder. Psychiatr Clin North Am. 2004;27(2):187-201.
36. Guy W ECDEU Assessment Manualfor Psychopharmacology. US Department of Health, Education, and Welfare publication (ADM) 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
37. Brown TE. Brown Attention Deficit Hyperactivity Disorder Scales for Adolescents and Adults. San Antonio, TX: The Psychological Corporation; 1996.
38. Sandra Kooij JJ, Marije Boonstra A, Swinkels SH, et al. Reliability, validity, and utility of instruments for self report and informant report concerning symptoms of ADHD in adult patients. J Atten Disord. 2008;1-1(4)445-458.
39. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6(R1). http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatorylnformation/Guidances/ucm073122.pdf. Accessed February 11,2013.
40. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000:85-93.
41. International Federation of Pharmaceutical Manufacturers and Associations. Medical Dictionary for Regulatory Activities (MedDRA), Version 11.1. Chantilly, VA: Northrop Grumman; 2009.
42. Posner K, Brent D, Lucas C, et al. Columbia Suicide Severity Rating Scale. http://www.maps.org/mdma/mtl-docs/c ssrsl 14-09-baseline.pdf. Accessed February 12, 2013.
43. Cohen J. The significance of a product moment r. In: Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
44. Turgay A, Ginsberg L, Sarkis E, et al. Executive function deficits in children with attention deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open label study. J Child Adolesc Psychopharmacol. 2010;20(6):503-511.
45. Katic A, Ginsberg L, Jam R, et al. Clinically relevant changes in emotional expression in children with ADHD treated with lisdexamfetamine dimesylate. J Atten Disord. 2012;16(5):384-397.
46. Biederman J, Seidman U, Petty CR, et al. Effects of stimulant medication on neuropsychological functioning in young adults with attention deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(7) :1150-1156.
47. Brown TE, Holdnack J, Saylor K, et al. Effect of atomoxetine on executive function impairments in adults with ADHD. J Atten Disord. 2011;15(2):130-138.
48. Faraone SM Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord. 2012;16(2):128-137.
49. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention deficit/hyperactivity disorder: a randomized, placebo controlled, double blind, parallel group, dose escalation study. J Clin Psychopharmacol. 2009;29(3):239-247.
50. Wigal T, Brams M, Gasior M, et al; 316-Study Group. Randomized, double blind, placebo controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention deficit/hyperactivity disorder: novel findings using the adult workplace environment design. Behav Brain Funct. 2010;6:34.
51. Weisler R, Young J, Mattingly G, et al; 304-Study Group. Long term safety and effectiveness of lisdexamfetamine dimesylate in adults with attention deficit/hyperactivity disorder. NS Spectr. 2009;14(10):573-585.
52. Biederman J, Mick E, Surman C, et al. A randomized, placebo controlled trial of OROS methylphenidate in adults with attention deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9) :829-835.
53. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended release in the treatment of adult ADHD: a randomized, controlled trial. NS Spectr. 2006;11(8):625-639.